Juno Therapeutics Inc (NASDAQ:JUNO) CFO Steve Harr sold 8,750 shares of the company’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the completion of the transaction, the chief financial officer now owns 772,082 shares in the company, valued at $34,558,390.32. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Juno Therapeutics Inc (JUNO) opened at $46.00 on Monday. Juno Therapeutics Inc has a 52-week low of $18.03 and a 52-week high of $63.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.77 and a current ratio of 4.77. The company has a market cap of $5,141.21, a P/E ratio of -13.61 and a beta of 2.33.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The company had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the prior year, the company posted ($0.57) earnings per share. Juno Therapeutics’s revenue for the quarter was up 115.4% compared to the same quarter last year. equities analysts forecast that Juno Therapeutics Inc will post -4.02 EPS for the current fiscal year.

Large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics during the second quarter valued at approximately $105,000. Advisor Group Inc. lifted its position in Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after acquiring an additional 1,439 shares during the last quarter. QS Investors LLC purchased a new stake in Juno Therapeutics during the second quarter valued at approximately $135,000. Finally, Bronfman E.L. Rothschild L.P. lifted its position in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 3,559 shares during the last quarter. 69.94% of the stock is owned by institutional investors.

A number of equities analysts have commented on JUNO shares. Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price on the stock in a research note on Tuesday, August 29th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $54.00 price target (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Raymond James Financial upped their price target on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a research report on Friday, November 3rd. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Finally, Standpoint Research reaffirmed a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $45.48.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://theolympiareport.com/2017/12/25/insider-selling-juno-therapeutics-inc-juno-cfo-sells-391650-00-in-stock.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.